Boston Scientific Corporation $BSX Shares Newly Acquired by Jackson Square Capital LLC

Key Points

• Jackson Square Capital acquired 55,164 Boston Scientific shares worth approximately $2.4 million in the third quarter; institutional investors collectively own 89.07% of the stock.
• Company insiders purchased 194,522 shares worth about $9.4 million over the past 90 days, including significant acquisitions by CEO Michael Mahoney and Director David Habiger.
• Boston Scientific recently exceeded quarterly earnings and revenue expectations, while shares traded near $44.68. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $68.23, despite several recent target-price reductions.

Jackson Square Capital LLC acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 55,164 shares of the medical equipment provider's stock, valued at approximately $2,408,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Kelleher Financial Advisors acquired a new position in Boston Scientific during the second quarter worth $25,000. Clal Insurance Enterprises Holdings Ltd acquired a new position in shares of Boston Scientific in the first quarter valued at approximately $28,000. Nvwm LLC lifted its stake in shares of Boston Scientific by 526.2% during the 3rd quarter. Nvwm LLC now owns 645 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 542 shares during the period. Rakuten Securities Inc. purchased a new position in Boston Scientific during the second quarter worth about $30,000. Finally, Cassaday & Co Wealth Management LLC acquired a new stake in shares of Boston Scientific in the first quarter worth approximately $32,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Michael Mahoney acquired 186,240 shares of the company's stock in a transaction dated Monday, August 3rd. The shares were bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the purchase, the chief executive officer owned 1,590,024 shares of the company's stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David Habiger acquired 2,100 shares of the company's stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have bought 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is owned by company insiders.

Boston Scientific Price Performance

Shares of Boston Scientific stock traded up $0.29 on Monday, hitting $44.68. The company had a trading volume of 5,151,036 shares, compared to its average volume of 18,517,102. Boston Scientific Corporation has a 52 week low of $41.38 and a 52 week high of $105.65. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The company has a market cap of $64.76 billion, a PE ratio of 18.08, a PEG ratio of 1.07 and a beta of 0.58. The business has a 50-day simple moving average of $46.06 and a 200-day simple moving average of $49.67.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The firm's quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts expect that Boston Scientific Corporation will post 3.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BSX. Jefferies Financial Group lowered their price target on Boston Scientific from $67.00 to $60.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Citigroup dropped their target price on Boston Scientific from $50.00 to $48.00 and set a "neutral" rating on the stock in a research report on Monday, October 5th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Boston Scientific in a research note on Friday, October 2nd. Robert W. Baird set a $56.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Finally, Sanford C. Bernstein reiterated an "outperform" rating and issued a $54.00 price target (down from $60.00) on shares of Boston Scientific in a research note on Saturday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $68.23.

Boston Scientific Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.